STOCK TITAN

Regeneron Pharmaceuticals, Inc. - REGN STOCK NEWS

Welcome to our dedicated page for Regeneron Pharmaceuticals news (Ticker: REGN), a resource for investors and traders seeking the latest updates and insights on Regeneron Pharmaceuticals stock.

Regeneron Pharmaceuticals Inc. (symbol: REGN) is a prominent American biotechnology company headquartered in Westchester County, New York, since its founding in 1988. The core mission of Regeneron is to discover, develop, and commercialize innovative products targeting a range of serious medical conditions. With a diverse portfolio, Regeneron focuses on therapies for eye diseases, cardiovascular conditions, cancer, and inflammatory disorders.

Among its marketed products, Eylea stands out as a treatment for wet age-related macular degeneration and other eye diseases. Praluent is designed to lower LDL cholesterol levels, while Dupixent addresses multiple immunological conditions. In the oncology sector, Libtayo is a key therapy, and Kevzara targets rheumatoid arthritis.

The company is also heavily invested in the development of monoclonal and bispecific antibodies, often in collaboration with Sanofi and other partners. These initiatives include cutting-edge technologies such as RNA interference (RNAi) with Alnylam and CRISPR-based gene editing with Intellia.

Regeneron's recent progress includes significant advancements in its clinical-stage pipeline, which comprises over 35 product candidates. The company's financial health remains robust, supported by strong revenue streams from collaboration with Sanofi and a strategic $3.0 billion share repurchase program authorized by the board.

Latest updates highlight the company's ongoing efforts in gene therapy, particularly in treating genetic deafness and solid tumors. Regeneron's commitment to pioneering genetic medicine and leveraging data insights from the Regeneron Genetics Center® positions it as a leader in the biopharmaceutical industry.

For more information, visit Regeneron Pharmaceuticals.

Rhea-AI Summary
Regeneron and Intellia Therapeutics announce an expanded research collaboration to develop CRISPR-based gene editing therapies for neurological and muscular diseases. The collaboration will leverage Regeneron's proprietary antibody-targeted viral vector delivery technologies and Intellia's Nme2Cas9 gene editing systems.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.19%
Tags
none
-
Rhea-AI Summary
Regeneron Pharmaceuticals announces FDA acceptance for Priority Review of odronextamab for the treatment of lymphoma.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.39%
Tags
none
-
Rhea-AI Summary
Regeneron Pharmaceuticals to report Q3 2023 financial results on November 2, 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.39%
Tags
conferences earnings
Rhea-AI Summary
Regeneron Pharmaceuticals and Sanofi's supplemental Biologics License Application for Dupixent to treat children aged 1 to 11 with eosinophilic esophagitis (EoE) has been accepted for Priority Review by the FDA. The target action date for the FDA decision is January 31, 2024. Dupixent is currently the only approved treatment for children and adults aged 12 years and older with EoE. The sBLA is supported by positive data from the Phase 3 EoE KIDS trial, showing Dupixent's efficacy and safety in children aged 1 to 11 with EoE. Safety results were consistent with the known safety profile of Dupixent. Priority review is granted to therapies that have the potential to provide significant improvements in the treatment of serious conditions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.27%
Tags
none
-
Rhea-AI Summary
Regeneron completes acquisition of Decibel Therapeutics, strengthening gene therapy and auditory programs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.19%
Tags
-
Rhea-AI Summary
AbCellera expands collaboration with Regeneron, increasing the number of targets from 4 to 8.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary
Regeneron Pharmaceuticals announces CFO retirement and successor
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Regeneron Pharmaceuticals announces the addition of Kathryn Guarini and David P. Schenkein to its Board of Directors. Guarini brings technology and business experience, while Schenkein has expertise in oncology and hematology. Marc Tessier-Lavigne has retired from the Board.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
management
-
Rhea-AI Summary
Regeneron Pharmaceuticals to participate in upcoming healthcare conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.14%
Tags
none
Rhea-AI Summary
Regeneron receives funding from BARDA for clinical development of next-generation COVID-19 monoclonal antibody therapy
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.44%
Tags
covid-19

FAQ

What types of diseases does Regeneron Pharmaceuticals focus on?

Regeneron focuses on eye diseases, cardiovascular conditions, cancer, and inflammatory disorders.

What are some of Regeneron's key products?

Key products include Eylea for eye diseases, Praluent for lowering LDL cholesterol, Dupixent for immunology, Libtayo for oncology, and Kevzara for rheumatoid arthritis.

Who are some of Regeneron's notable collaborators?

Regeneron collaborates with Sanofi, Alnylam, and Intellia on various projects, including monoclonal and bispecific antibodies, RNAi, and CRISPR-based gene editing.

What recent financial steps has Regeneron taken?

Regeneron has initiated a $3.0 billion share repurchase program and reported strong financial performance in the first quarter of 2024.

How does Regeneron leverage genetic medicine?

Regeneron utilizes data-powered insights from the Regeneron Genetics Center® and employs proprietary technologies like VelociSuite® to advance drug development.

What is the significance of Eylea in Regeneron's product portfolio?

Eylea is a crucial product for treating wet age-related macular degeneration and other eye diseases, contributing significantly to Regeneron's revenue.

What advancements has Regeneron made in gene therapy?

Regeneron is progressing in gene therapy for genetic deafness and solid tumors, showcasing promising early results in clinical trials.

What is Dupixent used for?

Dupixent is used in treating various immunological conditions and has shown significant growth since its launch, treating over 850,000 patients.

What technologies does Regeneron use for drug development?

Regeneron uses proprietary technologies such as VelociSuite®, which includes platforms for producing optimized human antibodies and bispecific antibodies.

How does Regeneron contribute to scientific discovery?

Regeneron pushes the boundaries of scientific discovery with pioneering genetic medicine platforms and data insights, aiming to develop transformative therapies.

Regeneron Pharmaceuticals, Inc.

Nasdaq:REGN

REGN Rankings

REGN Stock Data

119.62B
108.37M
1.6%
89.92%
1.68%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
TARRYTOWN